Effects of miR-150-5p on the growth and SOCS1 expression of rheumatoid arthritis synovial fibroblasts
OBJECTIVE: miR-150-5p has been implicated in the regulation and onset of immune diseases. We investigated the effects of miR-150-5p on the functions of RA synovial fibroblasts (RASFs).
METHOD: The binding site between suppressor of cytokine signaling 1 (SOCS1) and miR-150-5p was analyzed using European Bioinformatics Institute database, and the 3' UTR of SOCS1 mRNA, including the binding site, was amplified and ligated to the 3'-end of LUC2 gene in the pmirGL0 dual-luciferase vector. The pmirGL0 vector and corresponding mimics were subsequently co-transfected into 293T cells to compare the relative fluorescence intensity of LUC2 between the miR-150-5p mimics and the negative control (NC) mimics groups. Further, the RASF cell line MH7A was transfected with miR-150-5p or NC mimics and subjected to flow cytometric analysis, cell counting kit-8 assay, western blot analysis, qPCR, and enzyme-linked immunosorbent (ELISA) assay 48 h after transfection.
RESULTS: miR-150-5p mimics resulted in a lower cell apoptotic rate and proportion of cells in the S phase. Using a dual-luciferase reporter gene assay, we then found that SOCS1 is a potential target of miR-150-5p. Compared with NC mimics, miR-150-5p mimics significantly decreased the protein and mRNA expression levels of SOCS1. ELISA assay showed that miR-150-5p mimics increased interleukin-6 level in the cell culture medium but did not influence tumor necrosis factor-alpha levels.
CONCLUSIONS: Overall, the growth-promoting effect of miR-150-5p on MH7A cells may be attributed to the miR-150-5p-induced degradation of SOCS1 mRNA, suggesting a potential therapeutic target for RA.Key Points• SOCS1 is a potential target of miR-150-5p.• miR-150-5p promoted the growth of RASF cell line MH7A.• miR-150-5p increased the secretion of IL-6 but did not significantly affect TNF-α levels in MH7A cells.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:39 |
|---|---|
| Enthalten in: |
Clinical rheumatology - 39(2020), 3 vom: 26. März, Seite 909-917 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qiu, Mingliang [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.01.2021 Date Revised 05.01.2021 published: Print-Electronic ErratumIn: Clin Rheumatol. 2020 Jan 16;:. - PMID 31950440 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10067-019-04894-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30479922X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30479922X | ||
| 003 | DE-627 | ||
| 005 | 20231225115745.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10067-019-04894-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1015.xml |
| 035 | |a (DE-627)NLM30479922X | ||
| 035 | |a (NLM)31879859 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qiu, Mingliang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of miR-150-5p on the growth and SOCS1 expression of rheumatoid arthritis synovial fibroblasts |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2021 | ||
| 500 | |a Date Revised 05.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Clin Rheumatol. 2020 Jan 16;:. - PMID 31950440 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: miR-150-5p has been implicated in the regulation and onset of immune diseases. We investigated the effects of miR-150-5p on the functions of RA synovial fibroblasts (RASFs) | ||
| 520 | |a METHOD: The binding site between suppressor of cytokine signaling 1 (SOCS1) and miR-150-5p was analyzed using European Bioinformatics Institute database, and the 3' UTR of SOCS1 mRNA, including the binding site, was amplified and ligated to the 3'-end of LUC2 gene in the pmirGL0 dual-luciferase vector. The pmirGL0 vector and corresponding mimics were subsequently co-transfected into 293T cells to compare the relative fluorescence intensity of LUC2 between the miR-150-5p mimics and the negative control (NC) mimics groups. Further, the RASF cell line MH7A was transfected with miR-150-5p or NC mimics and subjected to flow cytometric analysis, cell counting kit-8 assay, western blot analysis, qPCR, and enzyme-linked immunosorbent (ELISA) assay 48 h after transfection | ||
| 520 | |a RESULTS: miR-150-5p mimics resulted in a lower cell apoptotic rate and proportion of cells in the S phase. Using a dual-luciferase reporter gene assay, we then found that SOCS1 is a potential target of miR-150-5p. Compared with NC mimics, miR-150-5p mimics significantly decreased the protein and mRNA expression levels of SOCS1. ELISA assay showed that miR-150-5p mimics increased interleukin-6 level in the cell culture medium but did not influence tumor necrosis factor-alpha levels | ||
| 520 | |a CONCLUSIONS: Overall, the growth-promoting effect of miR-150-5p on MH7A cells may be attributed to the miR-150-5p-induced degradation of SOCS1 mRNA, suggesting a potential therapeutic target for RA.Key Points• SOCS1 is a potential target of miR-150-5p.• miR-150-5p promoted the growth of RASF cell line MH7A.• miR-150-5p increased the secretion of IL-6 but did not significantly affect TNF-α levels in MH7A cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a MH7A | |
| 650 | 4 | |a Rheumatoid arthritis | |
| 650 | 4 | |a SOCS1 | |
| 650 | 4 | |a miR-150-5p | |
| 650 | 7 | |a 3' Untranslated Regions |2 NLM | |
| 650 | 7 | |a IL6 protein, human |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a MIRN150 microRNA, human |2 NLM | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a SOCS1 protein, human |2 NLM | |
| 650 | 7 | |a Suppressor of Cytokine Signaling 1 Protein |2 NLM | |
| 700 | 1 | |a Mo, Lisha |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Juxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Weina |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Xiangjuan |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Xinwang |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Weidong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical rheumatology |d 1987 |g 39(2020), 3 vom: 26. März, Seite 909-917 |w (DE-627)NLM012613037 |x 1434-9949 |7 nnns |
| 773 | 1 | 8 | |g volume:39 |g year:2020 |g number:3 |g day:26 |g month:03 |g pages:909-917 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10067-019-04894-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 39 |j 2020 |e 3 |b 26 |c 03 |h 909-917 | ||